

# CHUGAI PHARMACEUTICAL CO LTD

ISIN: JP3519400000 WKN: 4519 Asset Class: Stock



## Company Profile

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	1,366,426,000,000		1,336,537,000,000		1,063,661,000,000	
<b>Common stock capital</b>		73,202,000,000		73,202,000,000		73,202,000,000
<b>Fixed assets</b>	566,121,000,000		533,221,000,000		475,033,000,000	
<b>Equity capital of a company</b>		1,625,580,000,000		1,424,387,000,000		1,188,017,000,000
<b>Cash and cash equivalents</b>	458,674,000,000		222,169,000,000		267,753,000,000	
<b>Accrued liabilities</b>		5,739,000,000		6,067,000,000		5,046,000,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		288,217,000,000		423,730,000,000		327,422,000,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		18,749,000,000		21,641,000,000		23,255,000,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		743,000,000		813,000,000		1,105,000,000
<b>Total assets</b>	1,932,547,000,000	1,932,547,000,000	1,869,758,000,000	1,869,758,000,000	1,538,694,000,000	1,538,694,000,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	7,604	7,771	7,664
<b>Equity ratio</b>	84.12%	76.18%	77.21%
<b>Debt-equity ratio</b>	18.88%	31.27%	29.52%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	26.67%	29.51%	27.75%

# CHUGAI PHARMACEUTICAL CO LTD

ISIN: JP3519400000 WKN: 4519 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	1,111,367,000,000	1,259,946,000,000	999,758,000,000
<b>Net income</b>	325,472,000,000	374,429,000,000	302,995,000,000
<b>EBIT</b>	2,696,962,500	3,239,368,400	2,557,534,800
<b>Operating income before taxes</b>	443,821,000,000	531,166,000,000	419,385,000,000
<b>Cash Flow</b>	411,326,000,000	244,335,000,000	279,711,000,000
<b>Net interest income</b>	1,696,000,000	122,000,000	117,000,000
<b>Research and development expenses</b>	164,764,000,000	148,360,000,000	131,276,000,000
<b>Income taxes</b>	118,349,000,000	156,737,000,000	116,390,000,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	891,549	989,020	795,736

## Board of Directors

Christoph Franz	Member of Supervisory Board
James Sabry	Member of Supervisory Board
Iwaaki Taniguchi	Member of Supervisory Board
Mariko Momoi	Member of Supervisory Board
Masayuki Oku	Member of Supervisory Board
Motoo Ueno	Member of Supervisory Board
William Anderson	Member of Supervisory Board
Yoichiro Ichimaru	Member of Supervisory Board

## Members of Management Board

Osamu Okuda	Chairman of Managing Board
Hisafumi Yamada	Member of Executive Committee
Junichi Ebihara	Member of Executive Committee
Satoko Shisai	Member of Executive Committee
Shinji Hidaka	Member of Executive Committee
Tetsuya Yamaguchi	Member of Executive Committee
Toshiaki Itagaki	Member of Executive Committee
Yoshiyuki Yano	Member of Executive Committee